Instrumental Assessment of Physiotherapy and Onabolulinumtoxin-A on Cervical and Headache Parameters in Chronic Migraine
Overview
Affiliations
Introduction: The purpose of the present study is to compare the effect of the physiotherapy to onabolulinumtoxin-A, and their combination, in relation to cervical and headache parameters in patients with chronic migraine.
Methods: This is an observational cohort study conducted by a headache center and a physiotherapy degree course on 30 patients with chronic migraine. The patients were distributed in three groups of treatments for three months: onabolulinumtoxin-A only, physiotherapy only, and onabolulinumtoxin-A plus physiotherapy. The patients were evaluated, before and after each treatment, using the following: the postural assessment software SAPO for the forward head posture; the CROM goniometer for the cervical range of motion; the Migraine Disability Assessment Score for headache parameters.
Results: After 3 months of each treatment, the scores obtained for the headache-related disability and the frequency of migraine decreased significantly for all groups, but the pain intensity scores changed significantly only in the onabolulinumtoxin-A (p = 0.01) and in the onabolulinumtoxin-A plus physiotherapy groups (p = 0.007). On the other hand, the forward head posture was reduced significantly in the physiotherapy (p = 0.002) and in the onabolulinumtoxin-A plus physiotherapy groups (p = 0.003). The cervical range of motion increased significantly in certain directions in the physiotherapy group and in the onabolulinumtoxin-A plus physiotherapy groups.
Conclusions: The physiotherapy improved the cervical parameters. The onabolulinumtoxin-A decreased pain intensity. As a consequence, it can be said that the combined treatment was more useful than a mono-therapy alone. From our results, it can be concluded that onabolulinumtoxin-A plus physiotherapy could be a good option in the management of chronic migraine.
Manganotti P, Deodato M, DAcunto L, Biaduzzini F, Garascia G, Granato A Neurol Int. 2024; 16(4):673-688.
PMID: 39051212 PMC: 11270432. DOI: 10.3390/neurolint16040051.
Deodato M, Granato A, Buoite Stella A, Martini M, Marchetti E, Lise I Neurol Sci. 2024; 45(8):4015-4026.
PMID: 38806882 PMC: 11255006. DOI: 10.1007/s10072-024-07611-8.
Jeong G, Lee B J Clin Med. 2024; 13(6).
PMID: 38541838 PMC: 10971228. DOI: 10.3390/jcm13061612.
Deodato M, Granato A, Martini M, Sabot R, Buoite Stella A, Manganotti P Neurol Sci. 2024; 45(8):3923-3929.
PMID: 38396170 PMC: 11254968. DOI: 10.1007/s10072-024-07372-4.
Figas G, Kostka J, Pikala M, Kujawa J, Adamczewski T J Clin Med. 2024; 13(3).
PMID: 38337534 PMC: 10856133. DOI: 10.3390/jcm13030840.